Sun Pharma Advanced Research Company Ltd. Financials: Quarterly Results
Revenue
8.45
Cr.
PAT
-80.42
Cr.
EBITDA
-59.21
Cr.
Sun Pharma Advanced Research Company Ltd. Q3FY26 Financial Metrics
| Indicator | Dec-25 | Sep-25 | Jun-25 | Mar-25 | Dec-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 8.45 | 7.86 | 9.64 | 27.19 | 14.91 |
| Total Income From Operations (Cr.) | 8.45 | 7.86 | 9.64 | 27.19 | 14.91 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | -59.21 | -68.27 | -45.62 | -56.13 | -76.64 |
| P/L Before Exceptional Items & Tax (Cr.) | -67.99 | -75.79 | -51.81 | -60.67 | -79.44 |
| P/L After Tax from Ordinary Activities (Cr.) | -80.42 | -75.85 | -51.87 | -59.77 | -79.51 |
| Net Profit/Loss For the Period (Cr.) | -80.42 | -75.85 | -51.87 | -59.77 | -79.51 |
| Basic EPS | -2.48 | -2.34 | -1.60 | -1.84 | -2.45 |
FAQs
Sun Pharma Advanced Research Company Ltd. announced its quarterly results for Q3 FY2026 on February 9, 2026.
In Q3 FY2026, Sun Pharma Advanced Research Company Ltd. are as follows:
Revenue: ₹8.45 crore
Net Profit: ₹-80.42 crore.
For Q3 FY2026, Sun Pharma Advanced Research Company Ltd. posted ₹8.45 crore in revenue and ₹-80.42 crore in net profit.
Past quarterly results for Sun Pharma Advanced Research Company Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.